Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy, male and non-pregnant female subjects, 18 years of age or older.~2. A diagnosis of papulopustular rosacea with ≥30 inflammatory facial lesions at Baseline. Subjects must have no more than 2 nodular lesions, at Baseline.~3. Subjects with the presence of telangiectasia at Baseline.~4. Subjects with an erythema score of at least 2 on the Investigator Assessment of Erythema scale at Baseline.~5. Subjects with severe rosacea on the Investigators Global Assessment scale at Baseline.~Exclusion Criteria:~1. Subjects with steroid rosacea or subtype 3 (phymatous rosacea).~2. Subjects with nodular rosacea.~3. Standard exclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment (Type: EXPERIMENTAL): CLS001 (Omiganan) gel applied once daily
- Vehicle Gel (Type: PLACEBO_COMPARATOR): Vehicle gel applied once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).